Rafferty Asset Management’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $15.3M | Buy |
635,140
+190,422
| +43% | +$4.98M | 0.03% | 215 |
|
|
2026
Q1 | $12.5M | Sell |
444,718
-176,499
| -28% | -$4.7M | 0.05% | 210 |
|
|
2025
Q4 | $15.5M | Sell |
621,217
-18,716
| -3% | -$472K | 0.05% | 202 |
|
|
2025
Q3 | $16.3M | Buy |
639,933
+29,262
| +5% | +$722K | 0.05% | 197 |
|
|
2025
Q2 | $14.8M | Buy |
610,671
+73,279
| +14% | +$1.71M | 0.05% | 205 |
|
|
2025
Q1 | $13.6M | Sell |
537,392
-119,352
| -18% | -$3.12M | 0.06% | 203 |
|
|
2024
Q4 | $17.4M | Buy |
656,744
+67,007
| +11% | +$1.82M | 0.06% | 171 |
|
|
2024
Q3 | $17.1M | Sell |
589,737
-41,205
| -7% | -$1.2M | 0.06% | 172 |
|
|
2024
Q2 | $17.7M | Buy |
630,942
+29,588
| +5% | +$815K | 0.07% | 166 |
|
|
2024
Q1 | $16.7M | Buy |
601,354
+12,336
| +2% | +$342K | 0.06% | 176 |
|
|
2023
Q4 | $17M | Sell |
589,018
-10,856
| -2% | -$328K | 0.07% | 161 |
|
|
2023
Q3 | $19.9M | Buy |
599,874
+45,311
| +8% | +$1.6M | 0.12% | 115 |
|
|
2023
Q2 | $20.3M | Buy |
554,563
+45,628
| +9% | +$1.78M | 0.11% | 109 |
|
|
2023
Q1 | $20.8M | Buy |
508,935
+20,306
| +4% | +$877K | 0.14% | 104 |
|
|
2022
Q4 | $25M | Buy |
488,629
+183,222
| +60% | +$8.78M | 0.21% | 80 |
|
|
2022
Q3 | $13.4M | Buy |
305,407
+164,528
| +117% | +$7.99M | 0.14% | 108 |
|
|
2022
Q2 | $7.39M | Sell |
140,879
-39,379
| -22% | -$2.01M | 0.07% | 196 |
|
|
2022
Q1 | $9.33M | Sell |
180,258
-24,805
| -12% | -$1.29M | 0.06% | 209 |
|
|
2021
Q4 | $12.1M | Buy |
205,063
+9,494
| +5% | +$470K | 0.06% | 158 |
|
|
2021
Q3 | $8.41M | Buy |
195,569
+59,845
| +44% | +$2.65M | 0.06% | 189 |
|
|
2021
Q2 | $5.32M | Buy |
135,724
+18,703
| +16% | +$727K | 0.03% | 300 |
|
|
2021
Q1 | $4.24M | Buy |
117,021
+12,817
| +12% | +$455K | 0.03% | 321 |
|
|
2020
Q4 | $3.84M | Sell |
104,204
-12,822
| -11% | -$470K | 0.04% | 290 |
|
|
2020
Q3 | $4.08M | Sell |
117,026
-24,173
| -17% | -$848K | 0.05% | 215 |
|
|
2020
Q2 | $4.38M | Buy |
141,199
+82,718
| +141% | +$2.81M | 0.06% | 187 |
|
|
2020
Q1 | $1.81M | Sell |
58,481
-110,229
| -65% | -$3.76M | 0.08% | 167 |
|
|
2019
Q4 | $6.27M | Buy |
168,710
+143,668
| +574% | +$5.12M | 0.1% | 118 |
|
|
2019
Q3 | $854K | Buy |
25,042
+2,633
| +12% | +$95.7K | 0.01% | 573 |
|
|
2019
Q2 | $921K | Buy |
22,409
+8,156
| +57% | +$324K | 0.02% | 572 |
|
|
2019
Q1 | $574K | Buy |
+14,253
| New | +$571K | 0.01% | 641 |
|
|
2018
Q4 | – | Sell |
-5,140
| Closed | -$215K | – | 695 |
|
|
2018
Q3 | $215K | Buy |
+5,140
| New | +$198K | ﹤0.01% | 669 |
|
|
2016
Q3 | – | Sell |
-125,558
| Closed | -$4.19M | – | 521 |
|
|
2016
Q2 | $4.19M | Buy |
+125,558
| New | +$4.01M | 0.28% | 40 |
|
|
2015
Q3 | – | Sell |
-12,622
| Closed | -$402K | – | 597 |
|
|
2015
Q2 | $402K | Sell |
12,622
-118
| -0.9% | -$3.85K | 0.03% | 381 |
|
|
2015
Q1 | $421K | Buy |
12,740
+4,622
| +57% | +$147K | 0.03% | 363 |
|
|
2014
Q4 | $240K | Sell |
8,118
-6,580
| -45% | -$189K | 0.05% | 314 |
|
|
2014
Q3 | $412K | Buy |
14,698
+5,597
| +61% | +$157K | 0.04% | 187 |
|
|
2014
Q2 | $256K | Buy |
9,101
+20
| +0.2% | +$570 | 0.05% | 264 |
|
|
2014
Q1 | $277K | Sell |
9,081
-150
| -2% | -$4.47K | 0.06% | 219 |
|
|
2013
Q4 | $268K | Buy |
+9,231
| New | +$269K | 0.06% | 206 |
|
Other funds holding PFE
Rafferty Asset Management's PFE Position: Q2 2026 in Review
Rafferty Asset Management increased its Pfizer (PFE) stake by 43% in Q2 2026, buying an estimated $4.98M and bringing the position to 635,140 shares worth $15.3M. The position accounts for 0.03% of the portfolio, ranked #215.
Rafferty Asset Management first reported a position in PFE in Q4 2013 and has held it in 39 quarters since. The position peaked at $25M in Q4 2022. 2,818 funds tracked by Wall St. Rank hold PFE as of Q2 2026.
- Rafferty Asset Management held 635,140 shares of Pfizer worth $15.3M as of Q2 2026.
- Rafferty Asset Management bought 190,422 Pfizer shares in Q2 2026, an estimated $4.98M.
- Pfizer made up 0.03% of Rafferty Asset Management's portfolio in Q2 2026, its #215 holding.
- Rafferty Asset Management first reported a position in Pfizer in Q4 2013 and has held it in 39 quarters since.
- Rafferty Asset Management's Pfizer position peaked at $25M in Q4 2022.
- 2,818 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.
Based on Rafferty Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.